drugset / Trial / NCT04867707

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes

NCT04867707

Phase 2 Completed 14 enrolled University of Missouri-Columbia
NaSingle-groupOpen-labelTreatment

Summary

The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.

Timeline

Start
2021-07-14
Primary completion
2024-10-18
Completion
2024-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanamivir Small molecule 10 mg Inhaled